Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Abstract Background The efficacy and safety of upadacitinib in patients with ankylosing spondylitis (AS) and inadequate response/intolerance to biologic disease-modifying antirheumatic drugs (bDMARD-IR) were evaluated through 1 year in the SELECT-AXIS 2 study. Here, we assess 2-year efficacy, safety...

Full description

Bibliographic Details
Main Authors: Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert Davies Inman, Hideto Kameda, Walter Peter Maksymowych, Ivan Lagunes-Galindo, Xianwei Bu, Peter Wung, Koji Kato, Anna Shmagel, Atul Deodhar
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Arthritis Research & Therapy
Subjects:
Ankylosing spondylitis
Radiographic axial spondyloarthritis
Biologic DMARD
Inadequate response
Open-label extension
Refractory
Online Access:https://doi.org/10.1186/s13075-024-03412-8

Internet

https://doi.org/10.1186/s13075-024-03412-8

Similar Items